New Science Ventures
New Science Ventures (NSV) is a Connecticut- and London-based venture capital firm that invests in early- and late-stage companies that apply novel scientific approaches across Life Sciences and Information Technology. NSV provides capital, board-level guidance, and access to external networks to support company formation, financing, commercialization and exits.
New Science Ventures
Greenwich, Connecticut, United States, North America
Services
Equity investments (early & late stage)
Provides capital through equity financings across early and late stages, including participation in Series A–D and growth rounds and follow-on financings.
Strategic guidance and board-level expertise
Investment professionals provide governance, corporate strategy and clinical/technical development planning through board and advisory participation.
Network and partnership facilitation
Leverages external networks to introduce commercial, clinical, technical and investor partners, and to support syndicate formation and strategic partnerships.
Support for company formation and exit execution
Participates in company formation and supports pathways to exit including public listings and M&A through board support and transaction participation.
Equity investments (early & late stage)
Provides capital through equity financings across early and late stages, including participation in Series A–D and growth rounds and follow-on financings.
Strategic guidance and board-level expertise
Investment professionals provide governance, corporate strategy and clinical/technical development planning through board and advisory participation.
Network and partnership facilitation
Leverages external networks to introduce commercial, clinical, technical and investor partners, and to support syndicate formation and strategic partnerships.
Support for company formation and exit execution
Participates in company formation and supports pathways to exit including public listings and M&A through board support and transaction participation.
Portfolio
Developing autologous tissue regeneration products (NVD003, NVDX3). Reported Phase 1/2 five-year follow-up results, obtained RMAT designation for NVD003, and announced pediatric implantations in Phase 1b/2a trials and Series B financings.
#Regenerative medicine / clinical-stage biotechnology
Announced collaborations with Duke University to study cell-free RNA in polytrauma and advancing clinical programs including long-COVID research.
#Biotherapeutics / cell-free nucleic acid therapeutics
Develops oral small-molecule therapies (TYK2 inhibitors, NLRP3 inhibitors). Reported multiple clinical milestones including Phase 1 and Phase 2 trials and raised multiple financing rounds.
#Clinical-stage biopharmaceuticals (autoimmune/inflammatory disease)
NSV is a founding investor; company announced a merger to list on Nasdaq and commercial shipments of Speedster7t FPGA devices.
#Semiconductor / high-performance FPGAs
Develops radio-frequency thruster plasma propulsion systems for satellites. NSV led a $26M Series B financing to support commercialization and scaling.
#Space propulsion / aerospace
Raised $56M Series B with NSV as lead investor; developing on-demand personal rapid transit solutions.
#Transportation / Personal Rapid Transit (PRT)
Developing autologous tissue regeneration products (NVD003, NVDX3). Reported Phase 1/2 five-year follow-up results, obtained RMAT designation for NVD003, and announced pediatric implantations in Phase 1b/2a trials and Series B financings.
#Regenerative medicine / clinical-stage biotechnology
Announced collaborations with Duke University to study cell-free RNA in polytrauma and advancing clinical programs including long-COVID research.
#Biotherapeutics / cell-free nucleic acid therapeutics
Develops oral small-molecule therapies (TYK2 inhibitors, NLRP3 inhibitors). Reported multiple clinical milestones including Phase 1 and Phase 2 trials and raised multiple financing rounds.
#Clinical-stage biopharmaceuticals (autoimmune/inflammatory disease)
NSV is a founding investor; company announced a merger to list on Nasdaq and commercial shipments of Speedster7t FPGA devices.
#Semiconductor / high-performance FPGAs
Develops radio-frequency thruster plasma propulsion systems for satellites. NSV led a $26M Series B financing to support commercialization and scaling.
#Space propulsion / aerospace
Raised $56M Series B with NSV as lead investor; developing on-demand personal rapid transit solutions.
#Transportation / Personal Rapid Transit (PRT)